Remix Therapeutics logo

Remix Therapeutics Employee Directory

Biotechnology ResearchMassachusetts, United States51-200 Employees

Remix Therapeutics is a clinical-stage biotechnology company focused on reprogramming RNA processing with small-molecule therapies to address disease drivers at their origin, targeting conditions with high unmet medical need. Based in Watertown, Massachusetts, the company develops orally administered compounds intended to influence gene expression through RNA processing, aligning with a research-focused positioning in the biotechnology sector.

The lead candidate, REM-422, is described as a first-in-class RNA processing modulator currently in Phase 1 trials for acute myeloid leukemia, high-risk myelodysplastic syndrome, and adenoid cystic carcinoma. In 2026, Remix reported that final results from the Phase 1 dose-escalation portion of the ARIA study in ACC were accepted for an oral presentation at the ASCO Annual Meeting. The company focuses on therapies that address disease at its origin, with an emphasis on oncology and other conditions characterized by high unmet medical needs.

Find Remix Therapeutics employees' phone numbers or email addresses

Remix Therapeutics Global Highlights

Location
Employees

North America
58

Minus sign iconPlus sign icon
  • United States Of America
    57
  • Canada
    1

Remix Therapeutics's Leadership

  • Stylized image of a person
    R. G.
    Chief Financial Officer
    Phone icon
  • Stylized image of a person
    L. J.
    Business Owner
    Phone icon
  • Stylized image of a person
    F. B.
    Principal Scientist, Medicinal Chemistry
    Phone icon
  • Stylized image of a person
    R. E.
    Senior Research Associate I
    Phone icon
  • Stylized image of a person
    C. R.
    Computational Biologist
    Phone icon

Remix Therapeutics Employee Metrics

100%
50%
0%
2026
2025
  • Research
  • Operations
  • Finance
  • Human Resources
  • Program & Project Management
  • Other
  • Biotechnology
  • Entrepreneurship
  • Business
  • Accounting
  • Community & Social Services

Contact profiles from Remix Therapeutics

Name
Title
Contact Info
Location
Last Update
  • Stylized image of a person
    R. G.
    Chief Financial Officer
    Phone icon
    Jun 26, 2026
  • Stylized image of a person
    L. J.
    Business Owner
    Phone icon
    May 06, 2026
  • Stylized image of a person
    F. B.
    Principal Scientist, Medicinal Chemistry
    Phone icon
    Jun 26, 2026
  • Stylized image of a person
    R. E.
    Senior Research Associate I
    Phone icon
    Jun 26, 2026
  • Stylized image of a person
    C. R.
    Computational Biologist
    Phone icon
    Oct 24, 2024

Frequently Asked Questions

What is Remix Therapeutics known for?

Minus sign iconPlus sign icon
Remix Therapeutics was founded in 2018 operates in the Biotechnology Research industry. Explore Remix Therapeutics's company overview page for more information.

What is Remix Therapeutics's most common email format?

Minus sign iconPlus sign icon
Remix Therapeutics employees' email format typically follows the pattern of . Trying to find reliable and up-to-date employee contact data? Find more Remix Therapeutics email formats with LeadIQ.

How many employees does Remix Therapeutics have currently?

Minus sign iconPlus sign icon
Remix Therapeutics has approximately 52 employees as of July 2026. These team members are located across 1 continents, including North America.

Who are Remix Therapeutics's key employees and leadership?

Minus sign iconPlus sign icon

As of July 2026, Remix Therapeutics's key employees include:

  • Chief Financial Officer: R. G.
  • Business Owner: L. J.
  • Principal Scientist, Medicinal Chemistry: F. B.
  • Senior Research Associate I: R. E.
  • Computational Biologist: C. R.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.